Tablet Coating Market to exceed USD 1.4 billion by 2032, Says Graphical Research Powered by GMI
13 juin 2023 20h00 HE
|
Graphical Research
Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- Tablet Coating Market size is estimated to surpass USD 1.4 billion by 2032. The increasing adoption of orphan drugs and medications...
Osteo-Pharma and Emultech Announce Joint Venture to Develop First-in-Class Disease-Modifying Treatment for Osteoarthritis
17 nov. 2021 06h00 HE
|
Bone-Tech
AMSTERDAM, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Emultech and Osteo-Pharma today announced a joint venture, Bone-Tech, to develop what could be the first disease-modifying treatment for osteoarthritis...
Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
27 mars 2014 12h15 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 27, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality...
Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014
10 févr. 2014 15h26 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Pharmaceuticals Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
03 sept. 2013 09h46 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2014
14 août 2013 16h29 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
Elite Pharmaceuticals, Inc. Hires Industry Veteran Doug Plassche as Executive Vice President of Operations
12 août 2013 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP) today announced the appointment of industry veteran Doug Plassche as Executive Vice President of Operations...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corporate History
21 juin 2013 13h44 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 21, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
Elite Pharmaceuticals, Inc. Announces 2013 Fiscal Year End Conference Call on Monday, June 24, 2013
19 juin 2013 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 19, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Laboratories Files Citizen Petition With the FDA on Brompheniramine Maleate and Pseudoephedrine HCL Extended Release
10 juin 2013 13h54 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 10, 2013 (GLOBE NEWSWIRE) -- Elite Laboratories, a wholly owned subsidiary of Elite Pharmaceuticals, Inc. (collectively ""Elite" or the "Company") (OTCBB:ELTP) today announced...